Consider Switching Some VTE Patients to a Low-Dose Direct Oral Anticoagulant

June 2017

More patients will use LOW-dose direct oral anticoagulants (DOACs) long-term to prevent recurrent venous thromboembolism (VTE).

We're used to giving warfarin or a DOAC (Eliquis, etc) for 3 months for patients who have a VTE due to a short-term risk such as surgery or minor trauma.

And we know to use long-term anticoagulation to prevent a VTE recurrence for most patients at high risk...such as those with active cancer or a clotting disorder.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Antithrombotics Consider Switching Some VTE Patients to a Low-Dose Direct Oral Anticoagulant
Ear Health Use Antibiotic Drops Instead of Oral Antibiotics for Kids With Ear Tubes
Migraine Consider "Mini-Prophylaxis" for Some Women With Menstrual Migraine
Acute Pain Dispel the Myth That Ketorolac Is a Stronger NSAID
Psychiatry Have an "Exit Plan" for Antipsychotics in Dementia Patients
Opioids Avoid Codeine and Tramadol in Kids and Breastfeeding Women
PPIs Know When Short- or Long-Term Use of PPIs Is Appropriate
Diabetes Meds Expect a Limited Role for Basal Insulin/GLP-1 Agonist Combo Products
Fibromyalgia Emphasize Nondrug Measures for Fibromyalgia
Psychiatry Consider Ingrezza When Treatment Is Needed for Tardive Dyskinesia

Consider Switching Some VTE Patients to a Low-Dose Direct Oral Anticoagulant

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents